BIOCRYST PHARMACEUTICALS, INC. (BCRX) Current Ratio
- Current ratio · latest quarter: Value 2.32×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.32× | Current assets / current liabilities. $484.68M ÷ $208.85M ≈ 2.32× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 484.68M USD | Assets, Current |
| Current obligations | 208.85M USD | Liabilities, Current |
| Cash and equivalents | 154.97M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 110.76M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 6.06M USD | Inventory, Net |
| Payables | 11.46M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $484.68M | $208.85M | $154.97M | (m) | $110.76M | $6.06M | $11.46M | (m) | 2.32× |
| 2026-03-31 | $373.63M | $195.39M | $171.59M | (m) | $109.27M | $5.99M | $10.96M | (m) | 1.91× |
| 2025-12-31 | $404.35M | $196.07M | $89.74M | (m) | $106.82M | $5.40M | $15.83M | (m) | 2.06× |
| 2025-09-30 | $355.68M | $190.24M | $84.08M | (m) | $91.33M | $5.23M | $5.57M | (m) | 1.87× |
| 2025-06-30 | $398.46M | $177.16M | $88.03M | (m) | $91.18M | $5.04M | $8.59M | (m) | 2.25× |
| 2025-03-31 | $409.98M | $139.85M | $105.19M | (m) | $93.39M | $6.87M | $10.05M | (m) | 2.93× |
| 2024-12-31 | $421.97M | $160.38M | $104.71M | (m) | $79.07M | $8.09M | $11.64M | (m) | 2.63× |
| 2024-09-30 | $427.13M | $153.57M | $96.84M | $233.17M | $72.46M | $7.56M | $13.48M | (m) | 2.78× |
| 2024-06-30 | $363.46M | $129.06M | $78.41M | $193.62M | $68.76M | $4.45M | $7.79M | (m) | 2.82× |
| 2024-03-31 | $447.10M | $119.92M | $84.33M | $252.22M | $60.59M | $29.78M | $11.91M | (m) | 3.73× |
| 2023-12-31 | $495.97M | $149.99M | $110.64M | $278.34M | $56.95M | $28.68M | $20.89M | (m) | 3.31× |
| 2023-09-30 | $502.47M | $90.76M | $150.91M | $246.69M | $53.65M | $29.63M | $10.57M | (m) | 5.54× |
| 2023-06-30 | $511.06M | $93.50M | $146.22M | $264.45M | $57.67M | $27.03M | $13.89M | (m) | 5.47× |
| 2023-03-31 | $490.88M | $85.16M | $155.14M | $243.02M | $48.64M | $27.47M | $6.25M | (m) | 5.76× |
| 2022-12-31 | $516.50M | $105.51M | $304.77M | $119.54M | $50.60M | $27.53M | $14.36M | (m) | 4.90× |
| 2022-09-30 | $509.00M | $81.64M | $246.90M | $179.96M | $42.61M | $27.02M | $8.62M | (m) | 6.23× |
| 2022-06-30 | $494.85M | $95.39M | $272.57M | $144.91M | $41.49M | $23.38M | $12.02M | (m) | 5.19× |
| 2022-03-31 | $511.71M | $81.02M | $395.50M | $47.96M | $36.41M | $16.14M | $13.88M | (m) | 6.32× |
| 2021-12-31 | $566.14M | $103.72M | $504.39M | $3.21M | $29.41M | $15.79M | $27.81M | (m) | 5.46× |
| 2021-09-30 | $252.74M | $133.61M | $199.60M | $0.00 | $26.21M | $13.66M | $19.69M | (m) | 1.89× |
| 2021-06-30 | $265.80M | $115.60M | $210.31M | $8.11M | $27.62M | $9.85M | $10.09M | (m) | 2.30× |
| 2021-03-31 | $273.77M | $101.20M | $226.90M | $13.45M | $18.39M | $5.11M | $13.53M | (m) | 2.71× |
| 2020-12-31 | $323.80M | $105.65M | $272.13M | $28.24M | $8.65M | $7.04M | $18.71M | (m) | 3.06× |
| 2020-09-30 | $162.44M | $111.78M | $96.49M | $46.83M | $5.42M | $6.24M | $11.62M | (m) | 1.45× |
| 2020-06-30 | $203.84M | $102.65M | $173.47M | $15.94M | $4.00M | $5.23M | $9.35M | (m) | 1.99× |
| 2020-03-31 | $125.51M | $92.70M | $101.87M | $11.19M | $5.64M | (m) | $10.06M | (m) | 1.35× |
| 2019-12-31 | $164.34M | $92.33M | $114.17M | $22.05M | $22.15M | $0.00 | $13.99M | (m) | 1.78× |
| 2019-09-30 | $78.80M | $82.17M | $29.90M | $38.53M | $3.60M | $1.78M | $10.08M | (m) | 0.96× |
| 2019-06-30 | $103.72M | $71.95M | $30.76M | $61.39M | $3.60M | $1.00M | $8.30M | (m) | 1.44× |
| 2019-03-31 | $117.65M | $66.33M | $34.80M | $72.75M | $5.00M | $600.00K | $6.93M | (m) | 1.77× |
| 2018-12-31 | $114.35M | $69.48M | $26.73M | $77.74M | $4.29M | $1.65M | $7.77M | (m) | 1.65× |
| 2018-09-30 | $128.50M | $64.36M | $52.58M | $67.74M | $3.39M | $821.00K | $7.91M | (m) | 2.00× |
| 2018-06-30 | $92.67M | $74.17M | $27.10M | $53.64M | $2.34M | $221.00K | $4.12M | (m) | 1.25× |
| 2018-03-31 | $104.16M | $75.34M | $43.77M | $47.54M | $5.69M | $7.00K | $3.59M | (m) | 1.38× |
| 2017-12-31 | $125.39M | $74.84M | $50.28M | $64.11M | $6.12M | (m) | $6.34M | (m) | 1.68× |
| 2017-09-30 | $175.37M | $69.24M | $117.78M | $43.85M | $8.98M | (m) | $4.60M | (m) | 2.53× |
| 2017-06-30 | $92.26M | $58.94M | $39.70M | $40.98M | $3.33M | $1.30M | $1.84M | (m) | 1.57× |
| 2017-03-31 | $113.50M | $58.56M | $75.16M | $23.52M | $9.56M | $655.00K | $5.43M | (m) | 1.94× |
| 2016-12-31 | $66.99M | $54.36M | $22.10M | $32.55M | $8.77M | $500.00K | $4.27M | (m) | 1.23× |
| 2016-09-30 | $64.63M | $51.52M | $35.39M | $17.43M | $5.97M | $2.23M | $2.76M | (m) | 1.25× |
| 2016-06-30 | $46.11M | $56.19M | $8.66M | $27.08M | $2.23M | $1.95M | $5.05M | (m) | 0.82× |
| 2016-03-31 | $50.42M | $63.07M | $12.90M | $22.91M | (m) | $1.95M | $7.69M | (m) | 0.80× |
| 2015-12-31 | $63.79M | $62.26M | $28.90M | $22.66M | $6.24M | $1.61M | $9.31M | (m) | 1.02× |
| 2015-09-30 | $84.50M | $64.44M | $46.63M | $23.70M | (m) | (m) | $3.78M | (m) | 1.31× |
| 2015-06-30 | $107.09M | $63.77M | $76.78M | $17.58M | (m) | $1.31M | $3.82M | (m) | 1.68× |
| 2015-03-31 | $81.37M | $61.86M | $48.37M | $19.16M | (m) | $1.21M | $5.31M | (m) | 1.32× |
| 2014-12-31 | $89.34M | $57.29M | $54.54M | $18.23M | (m) | $683.00K | $2.85M | (m) | 1.56× |
| 2014-09-30 | $135.14M | $49.82M | $121.16M | $5.98M | (m) | (m) | $2.27M | (m) | 2.71× |
| 2014-06-30 | $138.25M | $44.94M | $121.52M | $10.59M | (m) | (m) | $2.36M | (m) | 3.08× |
| 2014-03-31 | $35.73M | $13.69M | $13.58M | $17.81M | (m) | (m) | $1.35M | (m) | 2.61× |
| 2013-12-31 | $42.12M | $15.26M | $21.16M | $16.89M | (m) | (m) | $4.17M | (m) | 2.76× |
| 2013-09-30 | $46.84M | $13.18M | $26.05M | $16.54M | (m) | (m) | $1.24M | (m) | 3.55× |
| 2013-06-30 | $33.53M | $11.96M | $19.77M | $9.36M | (m) | (m) | $989.00K | (m) | 2.80× |
| 2013-03-31 | $35.41M | $11.32M | $14.80M | $13.46M | (m) | (m) | $1.07M | (m) | 3.13× |
| 2012-12-31 | $41.98M | $17.22M | $20.89M | $14.71M | (m) | (m) | $3.97M | (m) | 2.44× |
| 2012-09-30 | $46.58M | $12.56M | $23.96M | $17.06M | (m) | $263.00K | $2.29M | (m) | 3.71× |
| 2012-06-30 | $45.06M | $19.11M | $21.92M | $12.96M | (m) | $263.00K | $3.33M | (m) | 2.36× |
| 2012-03-31 | $52.95M | $16.16M | $27.66M | (m) | (m) | $263.00K | $2.06M | (m) | 3.28× |
| 2011-12-31 | $52.86M | $26.30M | $16.44M | $25.27M | (m) | $263.00K | $2.50M | (m) | 2.01× |
| 2011-09-30 | $60.45M | $19.33M | $22.44M | $21.56M | (m) | $898.00K | $3.58M | (m) | 3.13× |
| 2011-06-30 | $79.88M | $21.96M | $17.01M | $40.58M | (m) | $898.00K | $5.01M | (m) | 3.64× |
| 2010-12-31 | $87.42M | $28.00M | $13.62M | (m) | (m) | $898.00K | $8.20M | (m) | 3.12× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |